Iovance Biotherapeutics

IOVA

Market cap $981M

SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 164,900 shares of Iovance's common stock to 11 new, non-executive employees.

Iovance Biotherapeutics remains a Sell due to ongoing dilution risk, sub-consensus revenue, and only modest margin improvements. Q3 revenue landed in the base case at $68 million, missing estimates, while gross margin improved to 29.6% (≤30% adjusted for D&A). Management reaffirmed FY25 revenue guidance and extended cash runway to Q2 2027, but execution and credibility issues persist.

Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales.

Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.

Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.

Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Igor Bilinsky - Chief Operating Officer Friedrich Graf Finckenstein - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Salim Syed Nicholas Lorusso - TD Cowen, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2025 Conference Call.

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance's common stock to nine new, non-executive employees.

Here's a great way to earn strong market returns over the long term: Identify companies that have been ignored or underestimated by most investors but have attractive prospects; buy their shares at a deep discount; and hold on to them for a long time. Picking out such corporations isn't easy, though.